Mcdaniel Terry & Co. Has $25.68 Million Stake in Stryker Corporation $SYK

Mcdaniel Terry & Co. lowered its position in Stryker Corporation (NYSE:SYK) by 2.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 64,907 shares of the medical technology company’s stock after selling 1,633 shares during the quarter. Stryker makes up about 2.1% of Mcdaniel Terry & Co.’s investment portfolio, making the stock its 21st largest holding. Mcdaniel Terry & Co.’s holdings in Stryker were worth $25,679,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Mar Vista Investment Partners LLC lifted its position in shares of Stryker by 10.2% in the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock valued at $33,572,000 after buying an additional 8,353 shares during the last quarter. United Services Automobile Association bought a new stake in Stryker in the 1st quarter valued at $2,857,000. AXS Investments LLC lifted its holdings in Stryker by 13.7% during the 1st quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock valued at $3,286,000 after purchasing an additional 1,062 shares during the last quarter. Park Edge Advisors LLC bought a new position in Stryker during the second quarter worth $679,000. Finally, Hendley & Co. Inc. raised its position in shares of Stryker by 60.3% in the second quarter. Hendley & Co. Inc. now owns 14,018 shares of the medical technology company’s stock valued at $5,546,000 after purchasing an additional 5,274 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of NYSE:SYK opened at $381.86 on Friday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $145.99 billion, a PE ratio of 50.58, a PEG ratio of 2.76 and a beta of 0.94. The firm has a 50 day moving average of $379.84 and a 200-day moving average of $379.73. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $5.92 billion. During the same period last year, the firm posted $2.81 earnings per share. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities research analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s dividend payout ratio (DPR) is 44.50%.

Insider Activity

In other news, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages recently commented on SYK. Redburn Partners set a $420.00 target price on shares of Stryker in a report on Thursday, September 18th. Rothschild & Co Redburn started coverage on Stryker in a research report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 target price on the stock. UBS Group set a $408.00 price target on Stryker in a report on Monday, October 13th. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Finally, Truist Financial dropped their target price on Stryker from $415.00 to $407.00 and set a “hold” rating for the company in a report on Wednesday, October 15th. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $432.24.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.